Previous studies showed that TNFR2+ Tregs increased in tumors of cervical cancer patients, and Foxp3+ tumor infiltrating immune cells in the central tumor area might be a biomarker for risk stratification in cervical cancer patients [17–19]. The gene discussed is FOXP3; the disease is cervical carcinoma.